Multiple Sclerosis
Read Time: 2 mins

Neuroprotective Therapies for Multiple Sclerosis

Copy Link
Published Online: Jun 27th 2012 European Neurological Review, 2012;7(3):189-195 DOI:
Authors: Beatriz Moreno, Pablo Villoslada
Quick Links:
Article Information

Multiple sclerosis (MS) is considered to be an autoimmune disease that is caused by the immune system attacking the central nervous system (CNS) leading to myelin loss and axonal damage, resulting in long-term disability. The pathophysiology of MS is complex with involvement of genetic and environmental factors that define the susceptibility to generate the autoimmune attack. In the last decade, several immunomodulatory drugs have been approved, including recombinant proteins such as interferon-beta, monoclonal antibodies such as natalizumab, or small chemicals including glatiramer acetate. In addition, there is a wide pipeline of new immunomodulators finishing Phase II or III trials. However, at present there are no approved treatments that directly reduce nervous system damage or enhance its repair. Novel neuroprotective agents have been identified in pre-clinical studies but their development is being prevented by the absence of appropriate understanding of the mechanisms of CNS damage by inflammation as well as by the lack of clinical platforms to test them. In this review, we describe the different mechanisms of axonal injury and discuss some of the principal therapeutic candidates that could provide neuroprotection in MS.


Multiple sclerosis, therapy, neuroprotection, regenerative therapies, neuroinflammation, neurodegeneration, demyelination, remyelination, axonal damage


Multiple sclerosis (MS) is not only an inflammatory demyelinating disease as classically described but also a neurodegenerative disease with significant axonal loss, affecting all regions of the central nervous system (CNS). MS patients show significant axonal loss and to less extent neuronal loss in the grey matter, as well as multi-focal demyelination, oligodendrocyte loss and grey and white atrophy.1,2 Current immunomodulatory therapies mainly treat the inflammatory component of the disease, however they may partially confer indirect neuroprotection due to prevention of the inflammatory damage that can produce degenerative changes in the long-term. Axonal and neuronal injury in MS occurs early in the disease course with damaged axons detected in histological specimens during the first year of diagnosis.3–6 The presence of damaged axons from the early stages of the disease has raised the current concept of axonal pathology in MS as the cumulative result of inflammatory events and emphasises the need for early neuroprotective intervention.

The term neuroprotection is not well defined, but it is understood as the activation of a number of processes essential to neuronal survival, differentiation and functioning.7 A neuroprotective therapy is the one with a beneficial effect in preserving the nervous system tissue and function against neurodegenerative diseases or brain injury. This effect may take the form of protecting neurons from apoptosis or degeneration and must not only target the pathogenic mechanism inducing tissue damage (e.g. restoring blood flow in stroke or preventing inflammation in MS). In the case of MS and considering that immunomodulation has achieved a significant control of the autoimmune process, now the current challenge is the development of neuroprotective and regenerative therapies8. This is critical for several reasons. First, immunomodulatory drugs may induce significant side effects, which are related with the level of immunomodulation achieved, limiting its dosage and therefore, its efficacy. For this reason, it is highly probable that some degree of residual inflammatory activity would remains, inducing tissue damage (immunopathology). Second, current immunomodulatory drugs target mainly the activity of the adaptive immune system, without preventing to significant extent the pro-inflammatory activity of resident microglia. Chronic microglia activation is present in all stages of the disease and it has been associated with axonal damage.9,10 For both reasons, in the near future is highly likely that even in presence of a good battery of highly efficacious immunomodulatory drugs, a certain degree of chronic inflammation within the CNS will remain, requiring neuroprotective strategies. Moreover, although a significant proportion of axonal and myelin loss is due to the acute inflammatory damage, imaging and pathological studies have shown that brain atrophy and axonal loss progress along time, indicating the presence of degenerative process.11,12

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:

Beatriz Moreno and Pablo Villoslada hold patent rights for the use of Methylthioadenosine and Neurotrophin agonists for treating multiple sclerosis and other neurological diseases. Pablo Villoslada has received consultancy fees from Roche, Novartis, Digna Biotech and Neurotech, and is founder and holds stock in Bionure Farma.


Beatriz Moreno, Centre of Neuroimmunology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Barcelona, Spain. E:




  1. Lucchinetti C, Brück W, Parisi J, et al., Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol, 2000;47(6):707–17.
  2. Sepulcre J, Goñi J, Masdeu JC, et al., Contribution of white matter lesions to grey matter atrophy in Multiple Sclerosis: Evidence from voxel-based analysis of T1 lesions in the visual pathway, Arch Neurol, 2009;66(2):173–9.
  3. Filippi M, Bozzali M, Rovaris M, et al., Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis, Brain, 2003;126(Pt 2):433–7.
  4. Kuhlmann T, Lingfeld G, Bitsch A, et al., Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, Brain, 2002;125(Pt 10):2202–12.
  5. De Stefano N, Narayanan S, Francis SJ, et al., Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability, Arch Neurol, 2002;59(10):1565–71.
  6. De Stefano N, Matthews PM, Filippi M, et al., Evidence of early cortical atrophy in MS: relevance to white matter changes and disability, Neurology, 2003;60(7):1157–62.
  7. Lipton SA, Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond, Nat Rev Drug Discov, 2006;5(2):160–70.
  8. Mullard A, Success of immunomodulators in MS shifts discovery focus to neuroprotection, Nat Rev Drug Discov, 2011;10(12):885–7.
  9. Moreno B, Jukes JP, Vergara-Irigaray N, et al., Systemic inflammation induces axon injury during brain inflammation, Ann Neurol, 2011;70(6):932–42.
  10. Ransohoff RM, Brown MA, Innate immunity in the central nervous system, J Clin Invest, 2012;122(4):1164–71.
  11. Steinman L, Multiple sclerosis: a two-stage disease, Nat Immunol, 2001;2(9):762–4.
  12. Trapp BD, Nave KA, Multiple sclerosis: an immune or neurodegenerative disorder?, Annu Rev Neurosci, 2008;31:247–69.
  13. Nave KA, Myelination and support of axonal integrity by glia, Nature, 2010;468(7321):244–52.
  14. Waxman SG, Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status, Nat Clin Pract Neurol, 2008;4(3):159–69.
  15. Barkhof F, Calabresi PA, Miller DH, Reingold SC, Imaging outcomes for neuroprotection and repair in multiple sclerosis trials, Nat Rev Neurol, 2009;5(5):256–66.
  16. Villoslada P, Biomarkers for multiple sclerosis, Drug News Perspect, 2010;23(9):585–95.
  17. Toledo J, Sepulcre J, Salinas-Alaman A, Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in Multiple Sclerosis, Mult Scler, 2008;14(7):906–12.
  18. Ferguson B, Matyszak MK, Esiri MM, Perry VH, Axonal damage in acute multiple sclerosis lesions, Brain, 1997;120(Pt 3):393–9.
  19. Trapp BD, Peterson J, Ransohoff RM et al., Axonal transection in the lesions of multiple sclerosis, N Engl J Med, 1998;338(5):278–85.
  20. Bitsch A, Schuchardt J, Bunkowski S, et al., Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation, Brain, 2000;123(Pt 6):1174–83.
  21. Neumann H, Medana IM, Bauer J, Lassmann H, Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases, Trends Neurosci, 2002;25(6):313–9.
  22. Matute C, Alberdi E, Ibarretxe G, Sánchez-Gómez MV, Excitotoxicity in glial cells, Eur J Pharmacol, 2002;447(2–3):239–46.
  23. Ziskin JL, Nishiyama A, Rubio M, et al., Vesicular release of glutamate from unmyelinated axons in white matter, Nat Neurosci, 2007;10(3):321–30.
  24. Ouardouz M, Coderre E, Basak A, et al., Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors, Ann Neurol, 2009;65(2):151–9.
  25. Ouardouz M, Coderre E, Zamponi GW, et al., Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors, Ann Neurol, 2009;65(2):160–6.
  26. Pampliega O, Domercq M, Villoslada P, et al., Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis, J Neuroimmunol, 2008;195(1–2):194–8.
  27. Pampliega O, Domercq M, Soria FN, et al., Increased expression of cystine/glutamate antiporter in multiple sclerosis, J Neuroinflammation, 2011;8:63.
  28. Bruck W, Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis, J Neurol, 2005;252 (Suppl. 5):v10–5.
  29. Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM, et al., Protein co-expression with axonal injury in multiple sclerosis plaques, Acta Neuropathol, 2006;111(4):289–99.
  30. Bö L, Dawson TM, Wesselingh S, et al., Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains, Ann Neurol, 1994;36(5):778–86.
  31. Lovas G, Szilágyi N, Majtényi K, et al., Axonal changes in chronic demyelinated cervical spinal cord plaques, Brain, 2000;123(Pt 2):308–17.
  32. Bjartmar C, Kinkel RP, Kidd G, et al., Axonal loss in normal-appearing white matter in a patient with acute MS, Neurology, 2001;57(7):1248–52.
  33. Kornek B, Storch MK, Weissert R, et al., Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions, Am J Pathol, 2000;157(1):267–76.
  34. Wilkins A, Chandran S, Compston A, A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons, Glia, 2001;36(1):48–57.
  35. Wilkins A, Compston A, Trophic factors attenuate nitric oxide mediated neuronal and axonal injury in vitro: roles and interactions of mitogen-activated protein kinase signalling pathways, J Neurochem, 2005;92(6):1487–96.
  36. Wilkins A, Majed H, Layfield R, et al., Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocytederived glial cell line-derived neurotrophic factor, J Neurosci, 2003;23(12):4967–74.
  37. Kornek B, Storch MK, Bauer J, et al., Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain, 2001;124(Pt 6):1114–24.
  38. Waxman SG, Acquired channelopathies in nerve injury and MS, Neurology, 2001;56(12):1621–7.
  39. Stys PK, Ransom BR, Waxman SG, Davis PK, Role of extracellular calcium in anoxic injury of mammalian central white matter, Proc Natl Acad Sci U S A, 1990;87(11):4212–6.
  40. Stys PK, Waxman SG, Ransom BR, Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger, J Neurosci, 1992;12(2):430–9.
  41. Trapp BD, Stys PK, Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis, Lancet Neurol, 2009;8(3):280–91.
  42. Black JA, Liu S, Hains BC, et al., Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE, Brain, 2006;129(Pt 12):3196–208.
  43. Kapoor R, Furby J, Hayton T, et al., Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial, Lancet Neurol, 2010;9(7):681–8.
  44. Brand-Schieber E, Werner P, Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis, Exp Neurol, 2004;189(1):5–9.
  45. Targ EF, Kocsis JD, 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve, Brain Res, 1985;328(2):358–61.
  46. Pitt D, Werner P, Raine CS, Glutamate excitotoxicity in a model of multiple sclerosis, Nat Med, 2000;6(1):67–70.
  47. Smith T, Groom A, Zhu B, Turski L, Autoimmune encephalomyelitis ameliorated by AMPA antagonists, Nat Med, 2000;6(1):62–6.
  48. Ouardouz M, Malek S, Coderre E, Stys PK, Complex interplay between glutamate receptors and intracellular Ca2+ stores during ischaemia in rat spinal cord white matter, J Physiol, 2006;577(Pt 1):191–204.
  49. Villoslada P, Arrondo G, Sepulcre J, et al., Memantine induces reversible neurologic impairment in patients with MS, Neurology, 2008;72(19):1630–3.
  50. Kalkers NF, Barkhof F, Bergers E, et al., The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study, Mult Scler, 2002;8(6):532–3.
  51. Sättler MB, Williams SK, Neusch C, et al., Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis, Am J Pathol, 2008;173(5):1496–507.
  52. Villoslada P, Genain CP, Role of nerve growth factor and other trophic factors in brain inflammation, Prog Brain Res, 2004;146:403–14.
  53. Villoslada P, Hauser SL, Bartke I, et al., Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system, J Exp Med, 2000;191(10):1799–806.
  54. Nagahara AH, Tuszynski MH, Potential therapeutic uses of BDNF in neurological and psychiatric disorders, Nat Rev Drug Discov, 2011;10(3):209–19.
  55. Cannella B, Pitt D, Capello E, Raine CS, Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination, Am J Pathol, 2000;157(3):933–43.
  56. Genoud S, Maricic I, Kumar V, Gage FH, et al., Targeted expression of IGF-1 in the central nervous system fails to protect mice from experimental autoimmune encephalomyelitis, J Neuroimmunol, 2005;168(1–2):40–5.

Further Resources

Share this Article
Related Content In Multiple Sclerosis
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72